BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 24108389)

  • 1. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
    Kangas L; Härkönen P; Väänänen K; Peng Z
    Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
    J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats.
    Komm BS; Vlasseros F; Samadfam R; Chouinard L; Smith SY
    Bone; 2011 Sep; 49(3):376-86. PubMed ID: 21658483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.
    Sampath TK; Simic P; Sendak R; Draca N; Bowe AE; O'Brien S; Schiavi SC; McPherson JM; Vukicevic S
    J Bone Miner Res; 2007 Jun; 22(6):849-59. PubMed ID: 17352644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.
    Ke HZ; Foley GL; Simmons HA; Shen V; Thompson DD
    Endocrinology; 2004 Apr; 145(4):1996-2005. PubMed ID: 14726439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
    Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
    Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
    Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
    J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
    Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
    Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
    Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
    Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
    Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
    Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
    Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
    Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats.
    Sato M; Zeng GQ; Turner CH
    Endocrinology; 1997 Oct; 138(10):4330-7. PubMed ID: 9322947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study.
    Chen HK; Ke HZ; Jee WS; Ma YF; Pirie CM; Simmons HA; Thompson DD
    J Bone Miner Res; 1995 Aug; 10(8):1256-62. PubMed ID: 8585430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats.
    Bourrin S; Ammann P; Bonjour JP; Rizzoli R
    Bone; 2002 Jan; 30(1):195-200. PubMed ID: 11792585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications.
    Kangas L; Unkila M
    Steroids; 2013 Dec; 78(12-13):1273-80. PubMed ID: 24055829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats.
    Ke HZ; Crawford DT; Qi H; Simmons HA; Owen TA; Paralkar VM; Li M; Lu B; Grasser WA; Cameron KO; Lefker BA; DaSilva-Jardine P; Scott DO; Zhang Q; Tian XY; Jee WS; Brown TA; Thompson DD
    J Bone Miner Res; 2006 Apr; 21(4):565-75. PubMed ID: 16598377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
    Iwamoto J; Yeh JK; Schmidt A; Rowley E; Stanfield L; Takeda T; Sato M
    Calcif Tissue Int; 2005 Aug; 77(2):119-26. PubMed ID: 16059775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
    Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
    Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.